IVF Treatment in India and UAE | Complete Patient Guide

• IDEAL CANDIDATES FOR IVF:

• Women with bilateral tubal occlusion or prior bilateral salpingectomy (absolute indication)

• Couples with severe male factor infertility (total motile sperm count <1 million; azoospermia requiring surgical sperm retrieval via TESA, PESA, micro-TESE, or MESA)

• Women with moderate-to-severe endometriosis (Stage III/IV, rAFS scoring) unresponsive to conservative surgical or medical management

• Patients with unexplained infertility after failed intrauterine insemination (IUI) cycles (typically 3–6 cycles)

• Women with diminished ovarian reserve (DOR) as evidenced by AMH <1.1 ng/mL, AFC <5–7, or elevated Day-3 FSH (>10–12 IU/L)

• Patients with PCOS who have failed ovulation induction and IUI

• Individuals or same-sex couples requiring donor eggs, donor sperm, or gestational surrogacy

• Patients with heritable genetic disorders who require PGT-M (Monogenic disease testing) to select unaffected embryos

• Oncofertility patients undergoing oocyte or embryo cryopreservation before gonadotoxic chemotherapy or pelvic radiation

• Women with uterine factor infertility (correctable by hysteroscopic surgery prior to IVF — e.g., septum resection, polypectomy, myomectomy)

• REQUIRED DIAGNOSTIC WORKUP (FEMALE):

• Day-2/3 hormonal panel: FSH, LH, Estradiol (E2), AMH, Prolactin, TSH, total Testosterone

• Antral Follicle Count (AFC) via transvaginal ultrasound (TVS)

• Hysteroscopy or saline infusion sonography (SIS/SHG) to assess uterine cavity

• Karyotyping (if recurrent pregnancy loss or advanced maternal age)

• Thrombophilia screen (Factor V Leiden, Prothrombin gene mutation, MTHFR, Protein C/S, Antithrombin III, Antiphospholipid antibodies) if recurrent implantation failure

• Endometrial Receptivity Analysis (ERA biopsy) for recurrent implantation failure

• Infectious disease screening: HIV, HBsAg, HCV, VDRL

• REQUIRED DIAGNOSTIC WORKUP (MALE):

• Semen analysis x2 (strict WHO 2021 criteria: concentration, total motility, progressive motility, strict morphology)

• DNA Fragmentation Index (DFI) by TUNEL or SCSA assay (>25% DFI associated with poor outcomes; >40% may indicate need for surgical sperm retrieval)

• Hormonal panel: FSH, LH, Testosterone, Prolactin

• Scrotal Doppler ultrasound (if clinical or subclinical varicocele suspected)

• Karyotyping + Y-chromosome microdeletion analysis (for severe oligospermia or non-obstructive azoospermia)

• CONTRAINDICATIONS:

• Active untreated uterine cavity pathology (large submucosal fibroid >4 cm distorting cavity)

• Severe, uncontrolled systemic illness placing pregnancy at unacceptable maternal or fetal risk (e.g., severe pulmonary hypertension, advanced renal failure)

• Active malignancy requiring immediate treatment (fertility preservation before treatment is appropriate; pregnancy is contraindicated during oncologic therapy)

• Premature Ovarian Insufficiency (POI) with no retrievable oocytes — donor egg IVF is the appropriate pathway

• Prior severe OHSS without corrective protocol modification (not an absolute contraindication but requires individualized GnRH antagonist + agonist trigger protocol)

IVF encompasses a spectrum of protocols and adjunct technologies. The appropriate approach is selected based on ovarian reserve, age, diagnosis, embryo quality, and history of prior IVF attempts.

1. STANDARD IVF WITH ICSI (Intracytoplasmic Sperm Injection)

In standard IVF, retrieved oocytes are placed in a culture dish with prepared sperm (conventional insemination), suitable when sperm parameters are normal. ICSI — the direct microinjection of a single morphologically selected sperm into each mature (MII) oocyte using a fine-tipped micropipette under inverted microscopy — is indicated for male factor infertility, low fertilization in prior cycles, surgical sperm use, or PGT. ICSI has become the globally dominant fertilization method, used in >70% of IVF cycles worldwide.

2. CONTROLLED OVARIAN STIMULATION (COS) PROTOCOLS

• GnRH Antagonist Protocol (standard for most patients): Stimulation begins Day 2–3 of menstrual cycle with daily subcutaneous gonadotropin injections. A GnRH antagonist (cetrorelix 0.25 mg/day or ganirelix) is added when lead follicle reaches 14 mm. Trigger injection given when ≥3 follicles ≥17–18 mm. Egg retrieval 34–36 hours post-trigger.

• Long GnRH Agonist Protocol (for endometriosis patients or poor responders in some centers): Down-regulation begins in the luteal phase of the preceding cycle, followed by stimulation. Longer duration but superior suppression.

• Minimal Stimulation IVF (Mini-IVF): Low-dose oral (clomiphene or letrozole) combined with minimal gonadotropins, targeting 3–5 eggs. Appropriate for poor responders or patients preferring reduced medication burden. Lower cost, lower OHSS risk, but fewer embryos available.

• Natural Cycle IVF: No stimulation; the single naturally dominant follicle is retrieved. Very low OHSS risk; suitable for patients who cannot receive exogenous gonadotropins (e.g., estrogen-sensitive cancers). Lower per-cycle success rate.

• Progestin-Primed Ovarian Stimulation (PPOS): Uses oral progestin (medroxyprogesterone acetate) instead of a GnRH antagonist to prevent premature LH surge. Requires a freeze-all strategy but allows flexible cycle scheduling — increasingly popular in Asia.

3. ADVANCED LABORATORY TECHNOLOGIES

• Time-Lapse Incubation (Embryoscope+, Miri TL): Embryos are cultured in a closed, undisturbed incubator with built-in camera systems capturing images every 5–20 minutes. AI algorithms (iDAScore, KIDScoreD5) annotate morphokinetic parameters automatically and rank embryos, reducing subjective variation in embryologist grading.

• Preimplantation Genetic Testing (PGT):

* PGT-A (Aneuploidies): NGS-based 24-chromosome screening. Biopsy of 5–10 trophectoderm cells at blastocyst stage (Day 5–6). Results in 10–14 days. Euploid single embryo transfer (eSET) gives 60–70% implantation rates and reduces miscarriage to <5%.

* PGT-M (Monogenic disorders): Linkage analysis + direct mutation detection for conditions such as BRCA1/2, Cystic Fibrosis, SMA, Huntington's. Requires a 3–4 month preparatory phase for probe design.

* PGT-SR (Structural Rearrangements): For couples carrying balanced translocations or inversions; detects unbalanced gametes.

• Sperm Selection Technologies:

* PICSI (Physiological ICSI): Selects sperm by hyaluronic acid binding capacity, correlating with lower DNA fragmentation. Reduces miscarriage rates.

* IMSI (Intracytoplasmic Morphologically Selected Sperm Injection): Uses 6,600x magnification (vs. 400x standard ICSI) to identify and exclude sperm with nuclear vacuoles.

* Microfluidic Sperm Sorting (ZyMōt): Chip-based selection using wall-shear-stress mimicking natural cervical canal, yielding sperm with significantly lower DFI without centrifugation-induced oxidative stress.

• Freeze-All + Frozen Embryo Transfer (FET): All embryos vitrified; transfer deferred to a subsequent cycle with optimized endometrial preparation. Reduces OHSS risk, allows PGT results, and achieves higher cumulative live birth rates than fresh transfer in high-responders. Endometrial preparation: hormonal (sequential estradiol + progesterone) or natural/modified natural cycle.

• Endometrial Receptivity Assessment:

* ERA (Endometrial Receptivity Analysis) / ERPeak: RNA-sequencing-based biopsy that identifies the personalized implantation window (pWOI) to time progesterone supplementation and transfer precisely. Recommended after ≥2 failed euploid transfers.

* EMMA + ALICE (Endometrial Microbiome / Chronic Endometritis Analysis): Identifies microbiome dysbiosis or Chronic Endometritis (CE) — present in up to 30% of recurrent implantation failure patients — allowing targeted antibiotic or probiotic correction.

• Surgical Sperm Retrieval (for azoospermia):

* TESA (Testicular Sperm Aspiration): Fine-needle aspiration; suitable for obstructive azoospermia.

* micro-TESE (Microsurgical Testicular Sperm Extraction): Operating microscope identification of dilated seminiferous tubules in non-obstructive azoospermia (NOA); highest sperm retrieval rates in NOA (40–60% vs. <25% with conventional TESE).

* PESA (Percutaneous Epididymal Sperm Aspiration): Obstructive azoospermia (post-vasectomy, CBAVD).

• Donor Egg IVF: Fresh or vitrified oocyte donation from screened, anonymous or known donors. Allows women with POI, DOR, advanced age, or heritable conditions to achieve pregnancy. Success rates per transfer approach 60–75% (donor-age-dependent).

• Surrogacy-linked IVF: Where legally permissible. India has highly regulated altruistic surrogacy (Surrogacy Regulation Act 2021 amendments apply). UAE regulations permit surrogacy only within specific legal frameworks for married couples.

PHASE 1 — INITIAL CONSULTATION & WORKUP (Weeks 1–2, typically done remotely before travel)

• Upload all prior medical records, semen analyses, and hormonal investigations to the GAF Healthcare patient portal.

• GAF coordinates a video consultation with the assigned fertility specialist (Reproductive Endocrinologist) for case review, protocol planning, and legal/regulatory briefing (particularly for surrogacy or donor egg cycles).

• Any outstanding investigations (ERA biopsy, PGT probe design, hysteroscopy, DFI testing) are identified. If hysteroscopy is required to correct a uterine cavity defect, this may be performed during an initial visit or locally before the main cycle.

• Legal documentation and consent forms (particularly for PGT, donor gametes, or surrogacy) are reviewed and completed.

PHASE 2 — OVARIAN STIMULATION MONITORING (Days 1–10 approximately; patient arrives in-country)

• Patient arrives in India or the UAE on Day 2–3 of her menstrual cycle (confirmed by GAF coordinator).

• Baseline TVS (antral follicle count, uterine cavity check) and Day-2/3 hormone panel are performed on arrival day.

• Daily/alternate-day subcutaneous gonadotropin self-injections (trained by clinic nurse).

• Serial TVS + serum estradiol monitoring every 1–2 days to titrate gonadotropin dose and timing of GnRH antagonist addition.

• Trigger injection administered when criteria are met (≥3 follicles ≥18 mm; estradiol levels consistent with oocyte maturity).

PHASE 3 — EGG RETRIEVAL (Day 10–14; Day-Care procedure)

• Transvaginal oocyte retrieval (TVOR) performed under IV conscious sedation or brief general anesthesia (propofol-based).

• Duration: 15–30 minutes. Patient observed for 2–4 hours post-procedure, then discharged.

• Embryologist performs oocyte denuding, maturity assessment, and ICSI/conventional insemination same day.

• Partner/sperm donor produces sample on retrieval day (or frozen surgical sperm is thawed).

• Post-retrieval: mild cramping, spotting normal. Oral analgesics (ibuprofen/paracetamol) prescribed. Progesterone luteal phase support initiated (vaginal micronized progesterone 400–800 mg/day, or injectable progesterone in oil if freeze-all strategy).

PHASE 4 — EMBRYO CULTURE & SELECTION (Days 1–6 post-retrieval; in-clinic laboratory phase, patient rests)

• Day 1: Fertilization check (2PN embryos confirmed).

• Days 2–3: Cleavage stage assessment (6–8 cell embryos; time-lapse AI scoring).

• Days 5–6: Blastocyst grading (Gardner system: expansion grade 1–6, ICM grade A/B/C, TE grade A/B/C). Only good-quality blastocysts (≥3BB) are considered for transfer or biopsy.

• If PGT-A: Trophectoderm biopsy and vitrification. Results communicated in 10–14 days (for fresh cycle planning) — in most PGT cycles, freeze-all is mandated.

• Patient may return home during PGT result wait period, then return for FET cycle.

PHASE 5 — EMBRYO TRANSFER (Day-Care; within fresh cycle or deferred FET cycle)

• Endometrial preparation confirmed by TVS (trilaminar pattern ≥7–8 mm, typically ≥8 mm preferred) and progesterone serum level.

• Single euploid blastocyst transfer (eSET) recommended to minimize twin risk; up to 2 embryos in selected cases (age >38, no PGT, poor quality embryos) with patient counseling.

• Ultrasound-guided transcervical catheter embryo transfer (soft catheter: Wallace, Cook Guardia) — a painless, 5–10 minute bedside procedure requiring no anesthesia.

• Patient rests 15–30 minutes post-transfer, then may resume normal light activity. Strict bed rest is NOT evidence-based and not required.

• Luteal phase support continued: vaginal progesterone ± estradiol patches/tablets.

PHASE 6 — POST-TRANSFER & PREGNANCY TEST (Days 1–14 post-transfer)

• Serum beta-hCG (quantitative) tested 12–14 days post-transfer (Day 25–28 equivalent).

• If positive: repeat hCG in 48 hours (should double); TVS at 6–7 weeks to confirm fetal cardiac activity.

• If negative: cycle review meeting with specialist to adjust protocol for subsequent attempt.

• Patients may fly home 5–7 days post-transfer (after completing the critical implantation window and initial monitoring), making total in-country stay approximately 14–18 days for a fresh cycle or 7–10 days for a FET cycle (if stimulation monitoring was done locally or remotely).

PHASE 7 — PREGNANCY HANDOVER & REMOTE FOLLOW-UP

• Positive pregnancy patients are transitioned to their local OB-GYN with a detailed clinical handover report prepared by the GAF team.

• Progesterone and estradiol supplementation schedule and weaning plan provided.

• GAF Healthcare's coordinator remains reachable for all queries through 12 weeks of pregnancy.